Ahmet AKGÜL, Zeynep Levent ÇIRAKLI, Vedat BAKUY, Mehmet ATAY, Mete GÜRSOY, Cabir GULMALİYEV

Nebivolol, metoprolol ve diltiazemin internal mammariyan arter greftindeki doku nitrik oksit sentaz aktivitesine etkisinin karşılaştırılması

Amaç: Bu çalışmada metoprolol ve diltiazeme kıyasla, insan internal mammariyan arterinde nitrik oksit sentaz aktivite düzeyine nebivololün etkisi araştırıldı. Çalışmaplanı:Çalışmaya koroner arter bypass greftleme planlanan 75 hasta (43 erkek, 32 kadın; ort. yaş 61.6±5.8 yıl; dağılım 41-76 yıl) dahil edildi. Hastalar randomize olarak üç gruba ayrıldı. Ameliyattan beş gün önce grup 1'de 50 mg metoprolol, grup 2'de 5 mg nebivolol ve grup 3'de 90 mg diltiazem tedavisi başlandı. Ameliyat sırasında internal mammariyan arterinden doku örnekleri alındı. Kantitatif sandwich enzim bağlı immünosorbent assay tekniği ile nitrik oksit sentaz aktivitesi ölçüldü ve serbest greft akımı hesaplandı.Bul gu lar: Ortalama doku nitrik oksit sentaz aktivitesi grup 1'de 0.4±0.0 U/mg, grup 2'de 2.4±0.3 U/mg ve grup 3'de 0.4±0.0 U/mg bulundu. Grup 2'de daha yüksek olmakla birlikte, gruplar arasında nitrik oksit sentaz aktivitesi açısından istatistiksel olarak anlamlı farklılık saptandı (p

Comparison of the effect of nebivolol, metoprolol and diltiazem on tissue nitric oxide synthase activity in internal mammary artery

Background: This study aims to evaluate the effects of nebivolol on nitric oxide synthase activity in human internal mammary artery compared to metoprolol and diltiazem. Methods: Seventy-five patients (43 males, 32 females; mean age 61.6±5.8 years; range 41 to 76 years) who were scheduled for coronary artery bypass grafting were enrolled in this study. Patients were assigned randomly to three groups. In group 1, 50 mg metoprolol, in group 2 5 mg nebivolol, and in group 3 90 mg diltiazem therapy was initiated five days before surgery. Samples of internal mammary artery were obtained intraoperatively. Nitric oxide synthase activity was measured by the quantitative sandwich enzyme-linked immunosorbent assay and graft free flow was calculated. Results: The mean tissue nitric oxide synthase activity was found to be 0.4±0.0 U/mg in group 1, 2.4±0.3 U/mg in group 2 and 0.4±0.0 U/mg in group 3. There was a significant difference in the mean tissue nitric oxide synthase activity among the groups (p

PDF

___

1. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248-58.
2. Hlatky MA, Shilane D, Boothroyd DB, Boersma E, Brooks MM, Carrié D, et al. The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. J Thorac Cardiovasc Surg 2011;142:829-35.
3. Rosenfeldt FL, He GW, Buxton BF, Angus JA. Pharmacology of coronary artery bypass grafts. Ann Thorac Surg 1999;67:878-88.
4. Jones EL, Lattouf OM, Weintraub WS. Catastrophic consequences of internal mammary artery hypoperfusion. J Thorac Cardiovasc Surg 1989;98:902-7.
5. Hillier C, Watt PA, Spyt TJ, Thurston H. Contraction and relaxation of human internal mammary artery after intraluminal administration of papaverine. Ann Thorac Surg 1992;53:1033-7.
6. Erdogan M, Okuducu N, Yamak B, Kısacıkoglu B. Can Lidocain HCL be used for topical vasodilatation of the internal mammarian artery? Turk Gogus Kalp Dama 2006;14:97-100.
7. Mert M, Ozkara A, Seren S, Gulcan F, Erdem CC, Suzer K. Influence of the topical and intraluminal papaverine applications on the internal thoracic artery flow. Turk Gogus Kalp Dama 2004;12:76-80.
8. Ding R, Feng W, Li H, Wang L, Li D, Cheng Z, et al. A comparative study on in vitro and in vivo effects of topical vasodilators in human internal mammary, radial artery and great saphenous vein. Eur J Cardiothorac Surg 2008;34:536-41.
9. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flowdependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
10. Félétou M, Köhler R, Vanhoutte PM. Nitric oxide: orchestrator of endothelium-dependent responses. Ann Med 2012;44:694-716.
11. Gupta S, Wright HM. Nebivolol: a highly selective beta1- adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008;26:189-202.
12. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
13. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-9.
14. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-600.
15. Jiang DJ, Jia SJ, Dai Z, Li YJ. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J Mol Cell Cardiol 2006;40:529-39.
16. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002;109:817-26.
17. Jiang JL, Zhang XH, Li NS, Rang WQ, Feng-Ye, Hu CP, et al. Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity. Cardiovasc Drugs Ther 2006;20:281-94.
18. Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009;32:962-8.
19. Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.
20. Ignarro LJ. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. Cardiovasc Ther 2008;26:115-34.
21. Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007;55:303-9.
22. Garbin U, Pasini AF, Stranieri C, Manfro S, Boccioletti V, Cominacini L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007;56:515-21.
23. Kandavar R, Higashi Y, Chen W, Blackstock C, Vaughn C, Sukhanov S, et al. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. J Am Soc Hypertens 2011;5:161-5.
24. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther 2000;292:606-9.
25. Sarikaya S, Onk A, Boztosun B, Kocabay G, Sahin M, Fedakar A, et al. The effect of nebivolol on internal mammary artery blood flow during coronary artery bypass graft surgery. Perfusion 2013. [Epub ahead of print]